A Diabetes Management, Current Therapies

The Bionic Pancreas Offers New Hope For type 1 Diabetes

There’s good news for those with type 1 diabetes.  The FDA has just approved a device (Medtronic MiniMed 670G) that automates keeping their blood sugar at healthy levels.  It will be available by Spring 2017. Referred to as a bionic pancreas, the system includes a glucose meter in the form of an electrode under the skin, an insulin pump strapped to the body, and an infusion patch connected to the pump.  A tiny catheter delivers insulin as needed. The system measures a patient’s glucose levels every five minutes and either administers or withholds insulin. The bionic pancreas does a far better job of maintaining the individual’s glucose levels within the normal range than previous therapies for those with type 1 diabetes.

Future versions will not only administer insulin to lower blood sugar, but can also provide glucagon to raise blood sugar. This technology means keeping individuals with Type 1 diabetes safe from the complications of diabetes that come when their blood sugar is out of the normal range.

 

Sodium-Glucose Transport Inhibitors Are Useful, But Have A Serious Drawback

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of diabetic medications that are highly useful for the treatment of type 2 diabetes. In the past, we tried to limit the amount of sugar excreted. We then gauged the effectiveness of diabetic control by whether a tablet added to urine showed color changes that revealed the presence of sugar. However, sodium-glucose inhibitors take the opposite approach; their goal is for people to pee out excess sugar. In addition to enabling people to get rid of excess sugar, sodium-glucose inhibitors can lower blood pressure and they can also have a modest impact on weight loss.  However, increased sugar in urine means an environment where yeasts can flourish increasing the likelihood of yeast infections.  This in turn limits the usefulness of the medication.

 

Menopause And Cardiovascular Disease

We recommend an aggressive approach in managing cardiac risk for women who are over 45 and have type 2 diabetes.   Type 2 diabetes is a cardiac risk equivalent disease. In most cases such women should be put on some version of statins.  After menopause, women lose much of their protection against heart disease. Statins are important for decreasing the inflammation that puts them at greater risk for cardiovascular disease.

 

Menopause And Disease

Menopause can be challenging for a woman with type 2 diabetes because hormonal fluctuations may influence blood glucose levels.  It may occur earlier for her than it would with a non-diabetic woman. She may experience sexual issues, such as lack of desire or vaginal dryness.  She also may experience mood swings. A menopausal woman with diabetes is likely to need more aggressive bone density testing.  She may have sleep issues, and getting this right is important because getting good sleep is essential for diabetes management. Type 2 diabetes also has a relationship with sleep apnea. If this is the case, the sleep apnea needs to be addressed.  In addition to treating specific symptoms, make sure that she exercises and that she gets her sleep.

 

Before Prescribing A New Medication, Make Sure The Patient Can Afford It

A recent patient in her 60s had a great response to one of the new medications.
She was given a prescription and a card to get her first month’s medication free, but then found that the new medication costs $1,000 a month.  She made too much money to get it free, but she didn’t make enough to be able to afford it. We now teach all our residents and young doctors to make sure that the patient can afford the medications they are prescribing.

Search Articles

Latest Articles

Subscribe to Updates

About Author

Mitzi Perdue is the widow of the poultry magnate, Frank Perdue.  She’s the author of How To Make Your Family Business Last and 52 Tips to Combat Human Trafficking.  Contact her at www.MitziPerdue.com

All Articles

An Economic Time Bomb for Life Insurance Owners

An Economic Time Bomb for Life Insurance Owners

An Economic Time Bomb for Life Insurance Owners View ArticleSearch ArticlesLatest ArticlesSubscribe to UpdatesAbout AuthorMitzi Perdue is the widow of the poultry magnate, Frank Perdue.  She’s the author of How To Make Your Family Business Last and 52 Tips to Combat...

read more
A System for Finding Family Business Blind Spots

A System for Finding Family Business Blind Spots

A System for Finding Family Business Blind SpotsThe Rosy Periwinkle The rosy periwinkle doesn’t look like a plant that’s worth $200 million a year. Except that its flowers are pink, it resembles the blue periwinkle commonly used as ground cover. To the desperate...

read more
My Favorite Post for This Year! Carmen, the Beautiful Carmen

My Favorite Post for This Year! Carmen, the Beautiful Carmen

My Favorite Post for This Year! Carmen, the Beautiful CarmenFor a peek inside the fecund mind of legendary hedge fund manager Roy Niederhoffer, come take a look at his analysis of the opera Carmen. Guaranteed, you’ll never before have seen such an original take on the...

read more

A New Way to Engage Next Gens in the Family Business

A New Way to Engage Next Gens in the Family BusinessWhat if Facebook met LinkedIn and decided to have a Family Business baby? In Esrock’s view, people in family businesses have a need for the kinds of information and encouragement that are unique to members of family...

read more
A Not-Secret Sauce for Investing

A Not-Secret Sauce for Investing

A Not-Secret Sauce for InvestingYou would think that doing business in Brazil would be an above-average risk proposition, right? Well maybe. But Matthew Wilkens has seen a truly impressive not-so-secret sauce that creates a spectacular exception. Even better, since...

read more
Is the Stock Market Long-in-the-Tooth?

Is the Stock Market Long-in-the-Tooth?

Is the Stock Market Long-in-the-Tooth?Is the current market long-in-the-tooth?  Should you pull back because it’s unreasonable to expect the market to keep on reaching new highs? “Not necessarily,” answers Eric Uchida Henderson, CFA and Chief Investment Officer of...

read more